Gene therapy trial for retinitis pigmentosa with RHO mutation
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have retinitis pigmentosa (an inherited eye disease that causes vision loss).
- A genetic test must confirm you have a specific change in the RHO gene (called c.403C>T, p.R135W).
- The eye being treated must still have some living cells that sense light and support vision.
- Your vision in the treated eye must be between counting fingers and reading 60 letters on an eye chart.
- You and your partner must agree to use birth control during the study and for at least 1 year after treatment.
- You cannot have had gene therapy or stem cell therapy for RP before, or certain eye surgeries in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This Phase 1/2 study tests a gene therapy treatment (BS01) in people with retinitis pigmentosa to try to improve or preserve vision. You may be a candidate if your vision in at least one eye is quite limited and you haven’t had certain gene therapies before.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.